SELLAS Life Sciences Group, Inc.
Nasdaq: SLSPharmaceutical Preparations · Entity-resolved by Clous
CIK0001390478
TickerSLS
ExchangeNasdaq
SIC2834
StateDE
FY end12-31
Illustrative profile — live data lights up when a server API key is configured.
Key financials
RevenueFY2023-12-31
$0
-100.0% YoY
Net IncomeFY2025-12-31
-$26.86M
+13.0% YoY
Total AssetsFY2025-12-31
$78.35M
+303.2% YoY
EquityFY2025-12-31
$70.87M
+648.8% YoY
Shares OutstandingFY2025-12-31
179.58M
—
Operating Cash FlowFY2025-12-31
-$28.39M
+19.8% YoY
Market
Market
SLSClose price
$8.05
Market cap
$1.5B
delayed EOD · as of 2026-06-18
Short interest & fails
Fails-to-deliver
SEC CNS fails · semi-monthly844.63K
shares failed · 2026-05-29
2026-05-29844.63K sh$9.18
2026-05-28709.17K sh$8.58
2026-05-2797.69K sh$8.12
2026-05-26676.11K sh$7.78
2026-05-22998.31K sh$7.56
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
| Concept | FY2022-12-31 | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Revenue | $1M | $0 | — | — | — | — |
| Net Income | -$41.3M | -$37.34M | -$30.88M | -$26.86M | +13.0% | — |
| Total Assets | $20.94M | $6.22M | $19.43M | $78.35M | +303.2% | — |
| Equity | $4.85M | -$7.98M | $9.47M | $70.87M | +648.8% | — |
| Operating Cash Flow | -$23.81M | -$31.41M | -$35.4M | -$28.39M | +19.8% | — |
| Shares Outstanding | — | — | — | 179.58M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001390478